The downgrade by Morgan Stanley from Overweight to Equal-Weight indicates a less optimistic outlook for Vaccitech. The significant reduction in the price target from $14 to $3.25 suggests that the analyst sees less upside potential in the stock, which could negatively impact its short-term price.